<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:media="http://search.yahoo.com/mrss/">
  <channel>
    <title>U.S.</title>
    <description>
      <![CDATA[]]>
    </description>
    <link>https://www.bioworld.com/rss</link>
    <language>en-us</language>
    <item>
      <title>Researchers hit back after colleagues removed from ADA meeting</title>
      <description>
        <![CDATA[Former principal officers of the American Diabetes Association (ADA) have hit back at the association’s board and CEO after it prohibited the distribution of an editorial published in its flagship journal <em>Diabetes Care</em> at the ADA’s meeting in New Orleans last Friday.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731723</guid>
      <pubDate>Wed, 10 Jun 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731723-researchers-hit-back-after-colleagues-removed-from-ada-meeting</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Misc/Hands-holding-paper.webp?t=1781120310" type="image/jpeg" medium="image" fileSize="147197">
        <media:title type="plain">Hands holding paper</media:title>
      </media:content>
    </item>
    <item>
      <title>Europe’s Alzecure, Orionis in $1B+ deals with Lilly, Novartis</title>
      <description>
        <![CDATA[Two companies with European ties signed billion-dollar deals with large pharma firms in the last two days to discover and develop molecular glue drugs, as well as to advance a preclinical Alzheimer’s disease prospect. For both companies, the up-front payments are relatively small, only $10 million for Alzecure Pharma AB, and just $40 million for Orionis Biosciences Inc. But it’s the back-end milestone amounts that are headline-grabbing.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731722</guid>
      <pubDate>Wed, 10 Jun 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731722-europes-alzecure-orionis-in-1b-deals-with-lilly-novartis</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Research-and-science/Purple-molecules.webp?t=1781123695" type="image/jpeg" medium="image" fileSize="178716">
        <media:title type="plain">Purple molecules</media:title>
      </media:content>
    </item>
    <item>
      <title>Sanofi phase III CIDP quit dents Dianthus; C1 mismatch?</title>
      <description>
        <![CDATA[Investors in Dianthus Therapeutics Inc. apparently chose to ignore subtleties in the difference between efforts with that firm’s claseprubart vs. those by competitor Sanofi SA, which said that the phase III Mobilize study testing riliprubart in chronic inflammatory demyelinating polyneuropathy (CIDP) will be stopped for futility.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731720</guid>
      <pubDate>Wed, 10 Jun 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731720-sanofi-phase-iii-cidp-quit-dents-dianthus-c1-mismatch</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Neurology/Neurology-nerve-cell-pain.webp?t=1682600134" type="image/jpeg" medium="image" fileSize="413083">
        <media:title type="plain">3D illustration of a nerve cell</media:title>
      </media:content>
    </item>
    <item>
      <title> Parabilis takes top spot, pricing largest biopharma IPO at $670M </title>
      <description>
        <![CDATA[Less than two months after Kailera Therapeutics Inc. made headlines with biopharma’s largest IPO to date, Parabilis Medicines Inc. has come along and surpassed it. The oncology-focused firm priced its upsized IPO of 3.5 million shares at $20 apiece for gross proceeds of $670 million, an amount that could rise to $770 million should underwriters exercise their full 5-million-share overallotment option.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731719</guid>
      <pubDate>Wed, 10 Jun 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731719-parabilis-takes-top-spot-pricing-largest-biopharma-ipo-at-670m</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Money/Virtual-IPO-word-with-stock-graph-and-arrow.webp?t=1775768546" type="image/jpeg" medium="image" fileSize="498778">
        <media:title type="plain">Virtual IPO word with stock graph and arrow</media:title>
      </media:content>
    </item>
    <item>
      <title>‘Disciplined’ $665M deal moves Oscotec’s cevidoplenib to Agios  </title>
      <description>
        <![CDATA[Agios Pharmaceuticals Inc.’s potential $665 million deal for Oscotec Inc.’s cevidoplenib, a phase III-ready oral SYK inhibitor to treat immune thrombocytopenia, marks a new chapter of development focused on cancer therapy resistance for Oscotec, CEO Yoon Tae-young said.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731828</guid>
      <pubDate>Tue, 09 Jun 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731828-disciplined-665m-deal-moves-oscotecs-cevidoplenib-to-agios</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Deals-and-MAs/Deal-handshake-with-coin-chart-background.webp?t=1704408549" type="image/jpeg" medium="image" fileSize="317806">
        <media:title type="plain">Deal handshake with coin, chart background</media:title>
      </media:content>
    </item>
    <item>
      <title>Competitive approach better than restricting deals with China?</title>
      <description>
        <![CDATA[The recent introduction of the bipartisan Biotech Investment National Security Act in the U.S. House has industry and venture capitalists urging lawmakers to take a breath, step back, and consider a less invasive approach than restricting U.S. biopharma deals with Chinese innovators.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731827</guid>
      <pubDate>Tue, 09 Jun 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731827-competitive-approach-better-than-restricting-deals-with-china</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Geographic-regions/Asia/china-us-deal.webp?t=1591119558" type="image/png" medium="image" fileSize="1457539">
        <media:title type="plain">China U.S. handshake</media:title>
      </media:content>
    </item>
    <item>
      <title>Wuxi Apptec insists it’s ‘not a Chinese military company’ </title>
      <description>
        <![CDATA[Wuxi Apptec isn’t going down without a fight after the U.S. Department of Defense added it to the Section 1260H list June 8 as a designated “Chinese military company,” which makes it a “biotechnology company of concern” under the Biosecure Act. “Such designation is mistaken and baseless,” the global contract research, development and manufacturing organization said in an open letter to its life sciences partners. “We will pursue every available avenue to correct this mistake.” That includes appealing the designation.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731710</guid>
      <pubDate>Tue, 09 Jun 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731710-wuxi-apptec-insists-its-not-a-chinese-military-company</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Misc/Wuxi-Apptec-signage.webp?t=1781036355" type="image/jpeg" medium="image" fileSize="104349">
        <media:title type="plain">Wuxi Apptec signage </media:title>
        <media:description type="plain">Credit: Wuxi Apptec</media:description>
      </media:content>
    </item>
    <item>
      <title>Columbia researchers use base editing to modify human embryo genome</title>
      <description>
        <![CDATA[Scientists at Columbia University have used base editing to make precise changes in the genomes of human embryos, avoiding the damage to chromosomes that occurs following two-stranded DNA cuts with conventional Crispr-Cas9 editing.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731708</guid>
      <pubDate>Tue, 09 Jun 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731708-columbia-researchers-use-base-editing-to-modify-human-embryo-genome</link>
      <media:content url="https://www.bioworld.com/ext/resources/BWS/BWS-library/DNA-gene-edit-genomics.webp?t=1747837759" type="image/jpeg" medium="image" fileSize="1061729">
        <media:title type="plain">DNA double helix under a magnifying glass</media:title>
      </media:content>
    </item>
    <item>
      <title>Pumps, patches and fixes at the ADA</title>
      <description>
        <![CDATA[Dexcom Inc. and Insulet Corp. reported new clinical trial data on their diabetes technologies at the 2026 Scientific Sessions of the American Diabetes Association in New Orleans, offering insights that could aid in clinical adoption. Abbott Laboratories, meanwhile, highlighted the risks of diabetic ketoacidosis (DKA) and presented data showing the growing challenge of identifying DKA as it can develop quickly and mimic common illnesses.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731707</guid>
      <pubDate>Tue, 09 Jun 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731707-pumps-patches-and-fixes-at-the-ada</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2022/12-8-Dexcom_G7_CGM.webp?t=1781033282" type="image/png" medium="image" fileSize="246353">
        <media:title type="plain">Dexcom G7 CGM</media:title>
        <media:description type="plain">Dexcom Inc.’s G7 continuous glucose monitoring system.</media:description>
      </media:content>
    </item>
    <item>
      <title>GLP-1s and more weigh in at ADA</title>
      <description>
        <![CDATA[GLP-1 receptor agonists remained center stage at the 2026 Scientific Sessions of the American Diabetes Association with Boehringer Ingelheim GmbH and Astrazeneca plc, joining the leaders, Eli Lilly and Co. and Novo Nordisk A/S, in presenting data for their respective GLP-1 drugs.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731706</guid>
      <pubDate>Tue, 09 Jun 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731706-glp-1s-and-more-weigh-in-at-ada</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Obesity/Close-up-of-injector-pen-in-hands.webp?t=1736374814" type="image/jpeg" medium="image" fileSize="117912">
        <media:title type="plain">Close-up of injector pen in hands</media:title>
      </media:content>
    </item>
    <item>
      <title>Competitive approach better than restricting deals with China?</title>
      <description>
        <![CDATA[The recent introduction of the bipartisan Biotech Investment National Security Act in the U.S. House has industry and venture capitalists urging lawmakers to take a breath, step back, and consider a less invasive approach than restricting U.S. biopharma deals with Chinese innovators.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731692</guid>
      <pubDate>Mon, 08 Jun 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731692-competitive-approach-better-than-restricting-deals-with-china</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Geographic-regions/Asia/china-us-deal.webp?t=1591119558" type="image/png" medium="image" fileSize="1457539">
        <media:title type="plain">China U.S. handshake</media:title>
      </media:content>
    </item>
    <item>
      <title>Clinical footwork pays off in Tango’s PDAC combo phase I/II</title>
      <description>
        <![CDATA[Tango Therapeutics Inc. will be sitting down with the U.S. FDA soon to discuss pivotal work ahead based on what Cantor analyst Eric Schmidt called “amazing” data from the phase I/II study of vopimetostat, a PRMT5 inhibitor, paired with Revolution Medicines Inc.’s RAS(ON) inhibitors in patients with MTAP-deleted and RAS-mutant metastatic pancreatic ductal adenocarcinoma (PDAC) as well as non-small cell lung cancer.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731691</guid>
      <pubDate>Mon, 08 Jun 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731691-clinical-footwork-pays-off-in-tangos-pdac-combo-phase-i-ii</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Cancer/Pancreatic-cancer-anatomy.webp?t=1780952171" type="image/jpeg" medium="image" fileSize="160961">
        <media:title type="plain">Pancreatic cancer anatomy</media:title>
      </media:content>
    </item>
    <item>
      <title>Nurix signs 4th and largest partnership to develop BTK degrader</title>
      <description>
        <![CDATA[Building on its partnerships with Gilead Sciences Inc., Sanofi SA and Pfizer Inc., Nurix Therapeutics Inc. brought on Roche Holding AG to help develop bexobrutideg, an oral degrader of Bruton’s tyrosine kinase (BTK).&nbsp;“I really can’t think of a better partner to maximize the opportunity for bexobrutideg to a wide range of patients,” Jason Kantor, Nurix’s chief business officer, told investors on a conference call, later pointing out that Roche has multiple drugs targeting B cells.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731690</guid>
      <pubDate>Mon, 08 Jun 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731690-nurix-signs-4th-and-largest-partnership-to-develop-btk-degrader</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Deals-and-MAs/Deal-partnership-chain-link.webp?t=1588276656" type="image/png" medium="image" fileSize="220515">
        <media:title type="plain">Gold chain link engraved with "partnership"</media:title>
      </media:content>
    </item>
    <item>
      <title> Incyte nabs potential VWD game-changer in Vega deal; J&amp;J buys Firefly</title>
      <description>
        <![CDATA[In its largest acquisition to date, Incyte Inc. snagged rights to phase III-stage VGA-039, a monoclonal antibody the firm said could offer a new standard of care in von Willebrand disease (VWD), in a buyout of Vega Therapeutics Inc. that includes a $1.25 billion up-front payment and up to $750 million tied to the achievement of sales milestones. The announcement was followed shortly by news of another buyout, Johnson & Johnson’s deal to acquire Firefly Bio Inc. for $1 billion in cash, both moves continuing this year’s trend of larger, more strategic M&A transactions.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731689</guid>
      <pubDate>Mon, 08 Jun 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731689-incyte-nabs-potential-vwd-game-changer-in-vega-deal-j-and-j-buys-firefly</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Deals-and-MAs/Collage-of-businesspeople.webp?t=1736806854" type="image/jpeg" medium="image" fileSize="308749">
        <media:title type="plain">Collage of businesspeople</media:title>
      </media:content>
    </item>
    <item>
      <title>FDA gets earful on CNPV pilot </title>
      <description>
        <![CDATA[The U.S. FDA’s year-old Commissioner’s National Priority Voucher (CNPV) pilot program played to mixed reviews at the agency’s June 4 listening session intended to get various stakeholders’ perspective on the ultra-accelerated review process being offered to qualifying drugs.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731633</guid>
      <pubDate>Fri, 05 Jun 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731633-fda-gets-earful-on-cnpv-pilot</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Regulatory/FDA-website-and-logo.webp?t=1632866648" type="image/png" medium="image" fileSize="443242">
        <media:title type="plain">FDA website and logo</media:title>
        <media:description type="plain">Credit: Postmodern Studio - stock.adobe.com</media:description>
      </media:content>
    </item>
    <item>
      <title>‘Disciplined’ $665M deal moves Oscotec’s cevidoplenib to Agios  </title>
      <description>
        <![CDATA[Agios Pharmaceuticals Inc.’s potential $665 million deal for Oscotec Inc.’s cevidoplenib, a phase III-ready oral SYK inhibitor to treat immune thrombocytopenia, marks a new chapter of development focused on cancer therapy resistance for Oscotec, CEO Yoon Tae-young said.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731632</guid>
      <pubDate>Fri, 05 Jun 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731632-disciplined-665m-deal-moves-oscotecs-cevidoplenib-to-agios</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Deals-and-MAs/Deal-handshake-with-coin-chart-background.webp?t=1704408549" type="image/jpeg" medium="image" fileSize="317806">
        <media:title type="plain">Deal handshake with coin, chart background</media:title>
      </media:content>
    </item>
    <item>
      <title>SCOTUS breathes new life into skinny labels</title>
      <description>
        <![CDATA[The U.S. Supreme Court handed Hikma Pharmaceuticals and the entire generic industry a big victory June 4 with its 9-0 opinion ensuring the future of skinny labels and correcting the Federal Circuit’s flawed understanding of infringed inducement.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731619</guid>
      <pubDate>Thu, 04 Jun 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731619-scotus-breathes-new-life-into-skinny-labels</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Drugs/Generic-drugs.webp?t=1588352361" type="image/png" medium="image" fileSize="183798">
        <media:title type="plain">Generic drugs and bottle</media:title>
      </media:content>
    </item>
    <item>
      <title>Autobahn on the fast track with bipolar thyroid agonist</title>
      <description>
        <![CDATA[Achieving high marks in the phase II Amplify-BD trial for bipolar I and II depression, Autobahn Therapeutics Inc.’s elunetirom, a brain-penetrant central nervous system thyroid hormone receptor agonist, or thyromimetic, is moving toward a registrational path and a clinical readout in major depressive disorder.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731618</guid>
      <pubDate>Thu, 04 Jun 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731618-autobahn-on-the-fast-track-with-bipolar-thyroid-agonist</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Neurology/Depression-and-medication.webp?t=1720465598" type="image/jpeg" medium="image" fileSize="70638">
        <media:title type="plain">Woman taking medication for mental illness</media:title>
      </media:content>
    </item>
    <item>
      <title>Zynlonta Lotis position in DLBCL strains ADC shares</title>
      <description>
        <![CDATA[ADC Therapeutics SA blamed patients’ advanced age on the death imbalance in the phase III Lotis-5 confirmatory trial testing Zynlonta (loncastuximab tesirine-lpyl) in combination with rituximab to treat relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL). Whatever the reason, Wall Street wasn’t pleased and shares (NYSE:ADCT) closed June 4 at $1.32, down 57%, or $1.77.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731616</guid>
      <pubDate>Thu, 04 Jun 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731616-zynlonta-lotis-position-in-dlbcl-strains-adc-shares</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Cancer/Diffuse-large-B-cell-lymphoma---isometric-view.webp?t=1780608328" type="image/jpeg" medium="image" fileSize="141240">
        <media:title type="plain">Diffuse large B-cell lymphoma - isometric view</media:title>
      </media:content>
    </item>
    <item>
      <title>Rubio reopening door with Gavi</title>
      <description>
        <![CDATA[Nearly a year after Health and Human Services Secretary Robert Kennedy announced the U.S. was cutting off funding for Gavi, a global vaccine alliance, Secretary of State Marco Rubio said his department is reengaging with the organization in light of the ongoing Ebola outbreak in central Africa. In testifying before a June 2 Senate Foreign Relations Committee hearing, Rubio said the State Department made the decision to reengage a few weeks earlier with Gavi. He provided no detail of what that engagement looks like.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731543</guid>
      <pubDate>Wed, 03 Jun 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731543-rubio-reopening-door-with-gavi</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Regulatory/Gavi-logo.webp?t=1780518810" type="image/jpeg" medium="image" fileSize="133960">
        <media:title type="plain">Smartphone with webpage of Gavi, The Vaccine Alliance</media:title>
        <media:description type="plain">Credit: Timon - stock.adobe.com</media:description>
      </media:content>
    </item>
    <item>
      <title>Mammogen raises $30M for blood-based breast cancer detection assay</title>
      <description>
        <![CDATA[Mammogen Inc. raised $30 million in equity financing in a series A round to support the clinical advancement and commercialization of its RNA-powered molecular diagnostics platform. The company’s lead product is Gentru-breast, a blood-based assay designed to detect molecular signatures associated with breast cancer from a simple blood draw. ]]>
      </description>
      <guid>http://www.bioworld.com/articles/731541</guid>
      <pubDate>Wed, 03 Jun 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731541-mammogen-raises-30m-for-blood-based-breast-cancer-detection-assay</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Money/Dollar-sign-between-hands.webp?t=1740610521" type="image/jpeg" medium="image" fileSize="123345">
        <media:title type="plain">Dollar sign between hands</media:title>
      </media:content>
    </item>
    <item>
      <title>Cytomx, Regeneron expand bispecifics deal to potential $4B</title>
      <description>
        <![CDATA[Cytomx Therapeutics Inc. and Regeneron Pharmaceuticals Inc., which inked a bispecifics-focused collaboration worth up to $2 billion in 2022, agreed to broaden their efforts in an expanded deal that provides Cytomx with additional funding up front as it advances its promising colorectal cancer candidate, varsetatug masetecan (Varseta-M), and fills the gap left by the recently terminated agreement with Astellas Pharma Inc.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731540</guid>
      <pubDate>Wed, 03 Jun 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731540-cytomx-regeneron-expand-bispecifics-deal-to-potential-4b</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Deals-and-MAs/Digital-handshake.webp?t=1683126686" type="image/jpeg" medium="image" fileSize="453851">
        <media:title type="plain">Digital handshake </media:title>
      </media:content>
    </item>
    <item>
      <title>Lilly enters $1.9B kidney disease deal for Ascidian’s exon editors</title>
      <description>
        <![CDATA[Once again, Eli Lilly and Co. has signed a billion-dollar deal, this time with Boston-based Ascidian Therapeutics Inc., a company that is barely four years old and one that is focused on treating human diseases by rewriting RNA. “Our technology, we call it RNA exon editing,” said Ascidian Chief Scientific Officer Robert Bell. “It edits RNA, not DNA … but it does so at the kilobase scale.”]]>
      </description>
      <guid>http://www.bioworld.com/articles/731539</guid>
      <pubDate>Wed, 03 Jun 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731539-lilly-enters-19b-kidney-disease-deal-for-ascidians-exon-editors</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Research-and-science/RNA-3D-illustration.webp?t=1725482193" type="image/jpeg" medium="image" fileSize="212050">
        <media:title type="plain">3D illustration of RNA</media:title>
      </media:content>
    </item>
    <item>
      <title>D&amp;D’s zabopegdutide shows more upbeat top-line phase II MASH data </title>
      <description>
        <![CDATA[D&D Pharmatech Inc. announced May 27 positive top-line tissue biopsy results of zabopegdutide (DD-01) from a 48-week phase II study of metabolic dysfunction-associated steatohepatitis (MASH), pushing company shares up 30% on the day.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731650</guid>
      <pubDate>Tue, 02 Jun 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731650-d-and-ds-zabopegdutide-shows-more-upbeat-top-line-phase-ii-mash-data</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Gastrointestinal/Liver-damage-fibrosis-cirrhosis.webp?t=1769528466" type="image/jpeg" medium="image" fileSize="677639">
        <media:title type="plain">Art concept for liver damage, such as fatty liver, fibrosis or cirrhosis</media:title>
      </media:content>
    </item>
    <item>
      <title>BMS-Hengrui deal strikes panic in Washington</title>
      <description>
        <![CDATA[On the heels of the multibillion-dollar licensing deal between Bristol Myers Squibb Co. and Jiangsu Hengrui Pharmaceuticals Co. Ltd., Chairman John Moolenaar (R-MI), of the House Select Committee on the Chinese Communist Party, sent a letter to Treasury Secretary Scott Bessent urging him to add biotechnology as a prohibited technology under the Comprehensive Outbound Investment National Security (COINS) Act of 2025.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731649</guid>
      <pubDate>Tue, 02 Jun 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731649-bms-hengrui-deal-strikes-panic-in-washington</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Geographic-regions/US/US-capital-washington-congress-government.webp?t=1588689267" type="image/png" medium="image" fileSize="2212023">
        <media:title type="plain">U.S. Capitol building</media:title>
      </media:content>
    </item>
    <item>
      <title>China launches long-awaited drug data protection rules </title>
      <description>
        <![CDATA[China’s National Medical Products Administration has issued final implementation measures for drug trial data protection that mark a significant step toward aligning China’s pharmaceutical intellectual property framework with global standards.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731647</guid>
      <pubDate>Tue, 02 Jun 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731647-china-launches-long-awaited-drug-data-protection-rules</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Devices/cybersecurity-data-lock.webp?t=1588286982" type="image/png" medium="image" fileSize="321597">
        <media:title type="plain">Cybersecurity data lock</media:title>
      </media:content>
    </item>
    <item>
      <title>Hanmi, Haisco win billion-dollar partnerships with Eli Lilly</title>
      <description>
        <![CDATA[Hanmi Pharmaceutical Co. Ltd. secured a $1.26 billion deal with Eli Lilly and Co. to out-license ex-Korea rights to sonefpeglutide (HM-15912), a Lapscovery-based glucagon-like peptide-2 analog in development for multiple indications, including an ongoing phase II study of short bowel syndrome. It was one of two billion-dollar Asian company deals signed by Lilly on June 1, with the second transaction involving Haisco Pharmaceutical Group Co. Ltd., of Beijing.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731645</guid>
      <pubDate>Tue, 02 Jun 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731645-hanmi-haisco-win-billion-dollar-partnerships-with-eli-lilly</link>
      <media:content url="https://www.bioworld.com/ext/resources/BW-source/2026/Hanmi-signage-6-1.webp?t=1780342948" type="image/jpeg" medium="image" fileSize="195343">
        <media:title type="plain">Hanmi signage</media:title>
        <media:description type="plain">Credit: Hanmi Pharmaceutical Co. Ltd.</media:description>
      </media:content>
    </item>
    <item>
      <title>ADCs, multispecific antibodies anchor $10B Pfizer-Innovent deal</title>
      <description>
        <![CDATA[Pfizer Inc. is paying Innovent Biologics Co. Ltd. $650 million up front and up to $9.85 billion in milestones, plus royalties, to collaborate across 12 early stage and de novo antibody-drug conjugates (ADCs) and multispecific antibodies for oncology.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731644</guid>
      <pubDate>Tue, 02 Jun 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731644-adcs-multispecific-antibodies-anchor-10b-pfizer-innovent-deal</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Cancer/Antibodies-attacking-cancer-cell.webp?t=1621365766" type="image/png" medium="image" fileSize="566115">
        <media:title type="plain">Antibodies attacking cancer cell</media:title>
      </media:content>
    </item>
    <item>
      <title>Fulcrum drops work on SCD drug pociredir; stock plummets</title>
      <description>
        <![CDATA[Shares of Fulcrum Therapeutics Inc. (NASDAQ:FULC) fell 54% after the company said it is discontinuing work on sickle cell disease (SCD) candidate pociredir, its only clinical-stage candidate, and reviewing strategic alternatives in the wake of the U.S. FDA’s safety concerns regarding the drug target.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731532</guid>
      <pubDate>Tue, 02 Jun 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731532-fulcrum-drops-work-on-scd-drug-pociredir-stock-plummets</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Hematologic/Sickle-cell-pic.webp?t=1589217567" type="image/png" medium="image" fileSize="558183">
        <media:title type="plain">Sickle cell illustration</media:title>
      </media:content>
    </item>
    <item>
      <title>FDA advises leveraging what’s already known in gene therapy R&amp;D</title>
      <description>
        <![CDATA[Rather than reinventing the wheel for every gene therapy that uses genome editing, the U.S. FDA is advising sponsors on leveraging existing knowledge, be it publicly available or platform-based, to more efficiently advance their products across multiple stages of development.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731529</guid>
      <pubDate>Tue, 02 Jun 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731529-fda-advises-leveraging-whats-already-known-in-gene-therapy-r-and-d</link>
      <media:content url="https://www.bioworld.com/ext/resources/BWS/BWS-library/DNA-gene-editing.webp?t=1730128296" type="image/jpeg" medium="image" fileSize="222415">
        <media:title type="plain">DNA double helix illustration with section being removed in red</media:title>
      </media:content>
    </item>
  </channel>
</rss>
